Breast Cancer

Elyse Lower, MD, discusses the importance of tucatinib in the treatment of patients with HER2-positive breast cancer.

Anita Johnson, MD, FACS, discusses existing disparities in cancer, studies that have helped to shed further light on the issue, and ongoing efforts being made to improve outcomes in all patients.

The FDA has granted a priority review to the new drug application seeking approval of plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

Diana Sutherland, NP, discusses the promise of CDK4 inhibitors in patients with metastatic breast cancer.

Dr Jhaveri and colleagues highlight key clinical trials in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Dr Jhaveri and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

In the first segment, Dr Jhaveri and colleagues discuss the unmet needs clinicians face in the treatment of patients with HER2-positive breast cancer.

Dr Kaklamani and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Dr Kaklamani and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

In the first segment, Dr Kaklamani and colleagues discuss the remaining unmet needs clinicians face despite recent advances in the treatment of patients with HER2-positive breast cancer.

Eribulin mesylate induced favorable responses and improved survival when used as a third or later line of treatment in patients with metastatic breast cancer, including those with triple-negative breast cancer.

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

Stephanie E. Weiss, MD, FASTRO and Eric M. Horwitz, MD, FABS, FASTRO, discuss ways to leverage radiation in the treatment of central nervous system metastases, areas of active investigation, and different available strategies that are improving outcomes for patients with cancer.

Stereotactic body radiotherapy can safely be used to treat patients with oligometastatic disease with 3 to 4 metastases or 2 metastases in close proximity to each other, according to results from the phase 1 NRG-BR001 trial.

Bhuvaneswari Ramaswamy, MD, discusses the potential utility of CDK4/6 inhibitors in the adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer.

Anita Johnson, MD, FACS, discusses racial disparities in outcomes across multiple tumor types.

Elyse Lower, MD, discusses the impact of tucatinib on the treatment of patients with HER2-positive breast cancer.

Enobosarm has been shown to induce a clinical benefit rate of 50% at 24 weeks in evaluable patients with measurable metastatic androgren receptor–positive, estrogen receptor–positive, metastatic breast cancer that has progressed on treatment with palbociclib.

Lajos Pusztai, MD, PhD, and Priyanka Sharma, MD, share closing thoughts on additional data they hope to see from the RxPONDER trial, and using these data in clinical practice for the treatment of HR+ early breast cancer.

Investigators are evaluating the addition of nivolumab to standard neoadjuvant therapy in patients with high-risk, estrogen-receptor–positive/ HER2-negative breast cancer to determine whether the PD-1 immune checkpoint inhibitor can improve recurrence rates.

Questions to consider when approaching the treatment of HR+, HER2-breast cancer based on the RxPONDER trial results.

Experts in breast cancer comment on NCCN guideline recommendations as they reflect the outcomes of the RxPONDER trial for HR+ early breast cancer.

Neoadjuvant pembrolizumab in combination with chemotherapy followed by adjuvant pembrolizumab monotherapy resulted in a significant improvement in event-free survival and pathologic complete response vs neoadjuvant chemotherapy alone in patients with high-risk, early-stage triple-negative breast cancer.

Leonie Voorwerk, discusses the rationale for examining the combination of atezolizumab plus carboplatin in patients with metastatic lobular breast cancer.

Saima Hassan, MD, PhD, FRCSC, discusses the mechanism of action of talazoparib in triple-negative breast cancer.